Recent performance snapshot and why Moderna is on watch

With no single headline event driving attention today, Moderna (MRNA) is drawing interest after a mixed performance, including a 1.8% gain over the past month and a stronger move over the past 3 months.

For context, the stock closed at US$54.26, with a market value near US$21.0b. This compares with a track record that includes a 75.8% year to date total return and about 115.4% over the past year, while the 3 year and 5 year total returns remain negative.

The recent 2.7% 1 day share price return and 4.2% 7 day share price return sit within a stronger trend, with a 90 day share price return of 37.9% and a 1 year total shareholder return of 115.4%. However, longer term total shareholder returns over 3 and 5 years remain deeply negative, so recent momentum is building off a much weaker multi year experience.

If Moderna has you looking more closely at high growth themes in healthcare, it could be worth widening the lens with our screener of 35 healthcare AI stocks

With Moderna posting strong recent gains but still carrying weak 3- and 5-year returns, and trading below the average analyst price target, the key question is whether this reset leaves upside on the table or if markets already price in future growth.

Most Popular Narrative: 69% Undervalued

With the last close at $54.26 against a narrative fair value of $175.00, the gap in expectations is wide and worth understanding in detail.

Despite the defunding of US governmental research and health services, Moderna remains in a commanding fundamental position. The company that made its name during the COVID-19 pandemic developing and manufacturing vaccines for the disease at breakneck pace also happened to have bagged a historic windfall in exchange for its performance. Less well-known is how Moderna reinvested the windfall in the wake of its success. The company has spent years plowing its profits into new innovations while maintaining a relatively pristine balance sheet for a company as large as it is. In biotech it is not uncommon for companies to keep low levels of debt, and Moderna is unique among its peers for its particularly low valuation relative to its assets. Currently, the company is trading below its book value, with outcomes depending on how any one of its numerous drug and treatment investments pan out. Even without any additional investment in medical innovation, the company has a lot of products in its pipeline ready to go.

This narrative, according to woodworthfund, leans heavily on a cash rich balance sheet, a full pipeline, and projected revenue growth feeding into a higher long term margin profile.

Result: Fair Value of $175.00 (UNDERVALUED)

However, this depends on a complex drug pipeline and clinical outcomes, while current revenue of US$1.9b and a net loss of US$2.8b keep execution risk front and center.

Another take using the market ratio

While the user narrative sees value up to $175.00, the current P/S of 11.1x tells a more cautious story. It is lower than the US Biotechs average of 11.8x, yet far above the fair ratio of 1.3x. This points to meaningful valuation risk if sentiment cools.

Next Steps

If this mix of optimism and caution leaves you unsure, take a closer look at the numbers yourself and decide where you stand. To understand what investors see as the key upside, review the 1 key reward

Looking for more investment ideas?

If Moderna has caught your attention, do not stop here. Broaden your watchlist with other stocks that fit different goals, from income to resilience.

• Target reliable income streams by reviewing companies in the 11 dividend fortresses that may suit a yield focused portfolio.
• Spot potential mispricings early by scanning the 60 high quality undervalued stocks before other investors catch on.
• Prioritize resilience in tough markets by checking companies in the 72 resilient stocks with low risk scores that score well on risk metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.